secwatch.observer — SEC 8-K summary
======================================

Issuer:     Abpro Holdings, Inc. (ABPO)
CIK:        0001893219
Form:       8-K/A
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001213900-25-105733
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abpro/Celltrion present preclinical data for CT-P72/ABP-102 at SITC 2025; poster in top 150
--------------------------------------------------------------------------------

- Poster selected as one of Top 150 abstracts out of >1,300 submissions at SITC 2025.
- CT-P72/ABP-102 demonstrated potent anti-tumor activity in HER2-high models, including Enhertu-resistant tumors.
- Dual-affinity engineering reduced on-target/off-tumor activity; favorable safety in non-human primates.
- Data supports advancement toward IND and first-in-human trial planned for next year.
- Built on Abpro's DiversImmune® platform for rapid engineering of next-generation antibodies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1893219/000121390025105733/0001213900-25-105733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1893219/000121390025105733/ea0263868-8ka1_abpro.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-105733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer